BPC-157 10mg
99.2% HPLC PurityA 15-amino-acid peptide derived from gastric juice, studied in tissue repair and gut research.

SKU: PEP-038-10MG
An 11-amino-acid peptide derived from erythropoietin's helix B, supplied as a 10mg lyophilised vial. Research use only. Preorder — ships with the first batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Preorder: dispatched once the next batch arrives, tracked with Australia Post
A 15-amino-acid peptide derived from gastric juice, studied in tissue repair and gut research.
A synthetic form of Thymosin Beta-4, studied in tissue repair and cell migration research.
An 11-amino-acid peptide derived from erythropoietin's helix B, supplied as a 10mg lyophilised vial.
It is studied for selective activation of the innate repair receptor without erythropoietic activity.
This product is currently available to preorder and ships once the first batch has been produced and tested. Strictly for in-vitro laboratory research only.
An 11-amino-acid peptide derived from erythropoietin's helix B, supplied as a 10mg lyophilised vial. It is studied for selective activation of the innate repair receptor without erythropoietic activity. All use is strictly for in-vitro laboratory research only.
This product is a preorder. It is not held in stock yet and ships with the first batch; you will be emailed when your order is dispatched.
Batch testing documentation is published for each batch once it has been produced and tested. Contact us before ordering if you need it first.
Store lyophilised product at −20°C, protected from light and moisture, and avoid repeated freeze-thaw cycles.
No. ARA-290 is supplied for in-vitro laboratory research only and is not approved for human consumption or therapeutic use. Scheduling attaches to the substance and changes over time; verify the current status against the TGA Poisons Standard.
ARA-290 (Cibinetide) 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to ARA-290. Provided for research context — not medical advice.
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van Velzen M, Heij L, Niesters M, et al. · Expert opinion on investigational drugs · 2014
PMID: 24555851
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception
Zhang W, Yu G, Zhang M · Peptides · 2016
PMID: 26774587
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression
Al-Onaizi MA, Thériault P, Lecordier S, et al. · Brain, behavior, and immunity · 2022
PMID: 34343617
Editorial
Tracey KJ · Molecular medicine (Cambridge, Mass.) · 2013
PMID: 24178588
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.